scholarly journals Human neural cell type‐specific extracellular vesicle proteome defines disease‐related molecules associated with activated astrocytes in Alzheimer's disease brain

2022 ◽  
Vol 11 (1) ◽  
Author(s):  
Yang You ◽  
Satoshi Muraoka ◽  
Mark P. Jedrychowski ◽  
Jianqiao Hu ◽  
Amanda K. McQuade ◽  
...  
2019 ◽  
Vol 13 ◽  
Author(s):  
Corinna Höfling ◽  
Emira Shehabi ◽  
Peer-Hendrik Kuhn ◽  
Stefan F. Lichtenthaler ◽  
Maike Hartlage-Rübsamen ◽  
...  

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Sang Su Kwak ◽  
Kevin J. Washicosky ◽  
Emma Brand ◽  
Djuna von Maydell ◽  
Jenna Aronson ◽  
...  

2020 ◽  
Vol 117 (41) ◽  
pp. 25800-25809 ◽  
Author(s):  
Shun-Fat Lau ◽  
Han Cao ◽  
Amy K. Y. Fu ◽  
Nancy Y. Ip

Alzheimer’s disease (AD) is the most common form of dementia but has no effective treatment. A comprehensive investigation of cell type-specific responses and cellular heterogeneity in AD is required to provide precise molecular and cellular targets for therapeutic development. Accordingly, we perform single-nucleus transcriptome analysis of 169,496 nuclei from the prefrontal cortical samples of AD patients and normal control (NC) subjects. Differential analysis shows that the cell type-specific transcriptomic changes in AD are associated with the disruption of biological processes including angiogenesis, immune activation, synaptic signaling, and myelination. Subcluster analysis reveals that compared to NC brains, AD brains contain fewer neuroprotective astrocytes and oligodendrocytes. Importantly, our findings show that a subpopulation of angiogenic endothelial cells is induced in the brain in patients with AD. These angiogenic endothelial cells exhibit increased expression of angiogenic growth factors and their receptors (i.e.,EGFL7,FLT1, andVWF) and antigen-presentation machinery (i.e.,B2MandHLA-E). This suggests that these endothelial cells contribute to angiogenesis and immune response in AD pathogenesis. Thus, our comprehensive molecular profiling of brain samples from patients with AD reveals previously unknown molecular changes as well as cellular targets that potentially underlie the functional dysregulation of endothelial cells, astrocytes, and oligodendrocytes in AD, providing important insights for therapeutic development.


2007 ◽  
Vol 179 (8) ◽  
pp. 5493-5503 ◽  
Author(s):  
Amir Afkhami-Goli ◽  
Farshid Noorbakhsh ◽  
Avril J. Keller ◽  
Nathalie Vergnolle ◽  
David Westaway ◽  
...  

2020 ◽  
Vol 16 (S3) ◽  
Author(s):  
Ornit Chiba‐Falek ◽  
Julio Barrera ◽  
Lingyun Song ◽  
Alexias Safi ◽  
Young Jun Yu ◽  
...  

2019 ◽  
Vol 15 ◽  
pp. P1496-P1496
Author(s):  
Kevin Green ◽  
Elizabeth Blue ◽  
Benjamin A. Logsdon ◽  
Brad Rolf ◽  
Shannon Rose ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-18 ◽  
Author(s):  
Henriette R. Frederiksen ◽  
Henriette Haukedal ◽  
Kristine Freude

Toll-like receptors mediate important cellular immune responses upon activation via various pathogenic stimuli such as bacterial or viral components. The activation and subsequent secretion of cytokines and proinflammatory factors occurs in the whole body including the brain. The subsequent inflammatory response is crucial for the immune system to clear the pathogen(s) from the body via the innate and adaptive immune response. Within the brain, astrocytes, neurons, microglia, and oligodendrocytes all bear unique compositions of Toll-like receptors. Besides pathogens, cellular damage and abnormally folded protein aggregates, such as tau and Amyloid beta peptides, have been shown to activate Toll-like receptors in neurodegenerative diseases such as Alzheimer’s disease. This review provides an overview of the different cell type-specific Toll-like receptors of the human brain, their activation mode, and subsequent cellular response, as well as their activation in Alzheimer’s disease. Finally, we critically evaluate the therapeutic potential of targeting Toll-like receptors for treatment of Alzheimer’s disease as well as discussing the limitation of mouse models in understanding Toll-like receptor function in general and in Alzheimer’s disease.


2020 ◽  
Vol 16 (S3) ◽  
Author(s):  
Alexi Nott ◽  
Inge Holtman ◽  
Nicole Coufal ◽  
Johannes CM Schlachetzki ◽  
Miao Yu ◽  
...  

2002 ◽  
Vol 109 (5-6) ◽  
pp. 837-855 ◽  
Author(s):  
H. Hampel ◽  
S. J. Teipel ◽  
G. E. Alexander ◽  
O. Pogarell ◽  
S. I. Rapoport ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document